Physician Views: Benchmarking the leading oral (non-insulin) diabetes brands

Which of the leading diabetes brands ('oral' or non-insulin) has had the biggest impact on changing treatment practice?  Which product do prescribers consider the best overall? Which available therapy are physicians least likely to use and which is the most clinically differentiated versus its rivals? Which of the leading diabetes brands do prescribers expect to gain the biggest increase in use over the next five years? – we are snap-polling US and EU5-based endocrinologists and primary care practitioners to find out.

To be notified when poll results and analysis become available, please click here

Which one of the following products has had the biggest impact on changing treatment practice for type 2 diabetes?

Byetta (exenatide)

Victoza (liraglutide)

Bydureon (exenatide)

Lyxumia/Adlynx (lixisenatide)

Eperzam/Tanzeum (albiglutide)

Trulicity (dulaglutide)

Januvia (sitagliptin)

Galvus (vildagliptin)

Onglyza (saxagliptin)

Nesina (atogliptin)

Tradjenta/Trajenta (linagliptin)

Farxiga/Forxiga (dapagliflozin)

Jardiance (empagliflozin)

Invokana (canagliflozin)

Glyxambi (empagliflozin/linagliptin)

Which one of the following treatments for type 2 diabetes is the best overall product?

Byetta (exenatide)

Victoza (liraglutide)

Bydureon (exenatide)

Lyxumia/Adlynx (lixisenatide)

Eperzam/Tanzeum (albiglutide)

Trulicity (dulaglutide)

Januvia (sitagliptin)

Galvus (vildagliptin)

Onglyza (saxagliptin)

Nesina (atogliptin)

Tradjenta/Trajenta (linagliptin)

Farxiga/Forxiga (dapagliflozin)

Jardiance (empagliflozin)

Invokana (canagliflozin)

Glyxambi (empagliflozin/linagliptin)

Which one of the following treatments for type 2 diabetes are you least likely to use? (if a particular drug is not approved in your market please exclude it when considering your answer)

Byetta (exenatide)

Victoza (liraglutide)

Bydureon (exenatide)

Lyxumia/Adlynx (lixisenatide)

Eperzam/Tanzeum (albiglutide)

Trulicity (dulaglutide)

Januvia (sitagliptin)

Galvus (vildagliptin)

Onglyza (saxagliptin)

Nesina (atogliptin)

Tradjenta/Trajenta (linagliptin)

Farxiga/Forxiga (dapagliflozin)

Jardiance (empagliflozin)

Invokana (canagliflozin)

Glyxambi (empagliflozin/linagliptin)

Which one of the following treatments for type 2 diabetes is the most clinically differentiated – in a positive way – versus the other therapies?

Byetta (exenatide)

Victoza (liraglutide)

Bydureon (exenatide)

Lyxumia/Adlynx (lixisenatide)

Eperzam/Tanzeum (albiglutide)

Trulicity (dulaglutide)

Januvia (sitagliptin)

Galvus (vildagliptin)

Onglyza (saxagliptin)

Nesina (atogliptin)

Tradjenta/Trajenta (linagliptin)

Farxiga/Forxiga (dapagliflozin)

Jardiance (empagliflozin)

Invokana (canagliflozin)

Glyxambi (empagliflozin/linagliptin)

Which one of the following treatments for type 2 diabetes do you expect to gain the biggest increase in use over the next five years?

Byetta (exenatide)

Victoza (liraglutide)

Bydureon (exenatide)

Lyxumia/Adlynx (lixisenatide)

Eperzam/Tanzeum (albiglutide)

Trulicity (dulaglutide)

Januvia (sitagliptin)

Galvus (vildagliptin)

Onglyza (saxagliptin)

Nesina (atogliptin)

Tradjenta/Trajenta (linagliptin)

Farxiga/Forxiga (dapagliflozin)

Jardiance (empagliflozin)

Invokana (canagliflozin)

Glyxambi (empagliflozin/linagliptin)

Semaglutide

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.

Reference Articles